ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Journal

Cancer Network Vol 31 No 3: March 2014

Gynecologic Cancers

In this review we discuss preoperative diagnosis and the role of pathology, and we summarize the current literature regarding the management of uterine sarcomas.

Gynecologic Cancers

Brain Tumors

Brain Tumors

A 70-year-old man presented at our institution for a second opinion regarding diagnosis of a urinary bladder mass. He had a 3-year history of worsening urinary incontinence and urgency, for which he had undergone colonoscopy, as well as testing for prostate issues; all test results were negative.

This article reviews the rationale for nanoparticle formulations of existing or previously investigated cytotoxic drugs, describe currently approved nanoparticle formulations of drugs, and discusses some of the most promising clinical trials currently underway.

In this interview we discuss ASCO's first trial, TAPUR (Targeted Agent and Profiling Utilization Registry), which is examining 17 different commercially available drugs in settings outside of their indication.

Leukemia & Lymphoma

As we learn more about the biology of AML, it appears that 7+3 only rarely clears residual leukemic clones in patients with higher-risk disease. New therapies are needed that can target and eradicate resistant subclones early in the disease course.

Leukemia & Lymphoma

‘7+3’ Still Remains the Best Option for Most PatientsAcute myeloid leukemia (AML) is a heterogeneous disorder, with subgroups best classified by discrete mutations detectable by cytogenetic or molecular genetic

Leukemia & Lymphoma

Prostate Cancer

An uncommon but significantly burdensome sequela of therapy for prostate cancer is pubic bone osteomyelitis in association with a pubosymphyseal urinary fistula.

Prostate Cancer

Gastrointestinal Cancer

In this article, we review seminal articles that have evaluated the molecular architecture of pancreatic cancer. We compare the methods used and the molecular subtypes defined, and assess the predominant subgroups in order to better understand which therapies may improve patient outcomes.

Gastrointestinal Cancer

By clicking Accept, you agree to become a member of the UBM Medica Community.